Burrill Starts Navidea Biopharmaceuticals (NAVB) at Market Outperform
Tweet
Share
E-mailGet Alerts NAVB Hot Sheet
Price: $0.04 --0%
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
4 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Burrill initiates coverage on Navidea Biopharmaceuticals (NYSE: NAVB) with a Market Outperform. PT $5.00.
The firm comments, "Navidea is currently seeking regulatory approval of Lymphoseek, a precision radiopharmaceutical agent used for intraoperative lymphatic mapping, and in our opinion, addresses a $300 MM worldwide market. In addition, the company has in-licensed NAV4694 and NAV5001, which are intended to aid in the diagnosis of Alzheimer’s and Parkinson’s diseases, respectively. All three products address large markets, approaching $1.5 B worldwide. With the potential for a Lymphoseek approval (April 30, 2013), partner Cardinal Health (CAH, Not Rated) to generate revenues in the near-term and a pipeline of diagnostic products which can help usher in an era of personalized treatments for indications of large unmet medical need, we believe Navidea represents an undervalued opportunity with multiple near-term drivers poised to create shareholder value in 2013."
For an analyst ratings summary and ratings history on Navidea Biopharmaceuticals click here. For more ratings news on Navidea Biopharmaceuticals click here.
Shares of Navidea Biopharmaceuticals closed at $2.97 yesterday.
The firm comments, "Navidea is currently seeking regulatory approval of Lymphoseek, a precision radiopharmaceutical agent used for intraoperative lymphatic mapping, and in our opinion, addresses a $300 MM worldwide market. In addition, the company has in-licensed NAV4694 and NAV5001, which are intended to aid in the diagnosis of Alzheimer’s and Parkinson’s diseases, respectively. All three products address large markets, approaching $1.5 B worldwide. With the potential for a Lymphoseek approval (April 30, 2013), partner Cardinal Health (CAH, Not Rated) to generate revenues in the near-term and a pipeline of diagnostic products which can help usher in an era of personalized treatments for indications of large unmet medical need, we believe Navidea represents an undervalued opportunity with multiple near-term drivers poised to create shareholder value in 2013."
For an analyst ratings summary and ratings history on Navidea Biopharmaceuticals click here. For more ratings news on Navidea Biopharmaceuticals click here.
Shares of Navidea Biopharmaceuticals closed at $2.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Resumes EQT Corp. (EQT) at Hold
- JMP Securities Starts The RMR Group Inc. (RMR) at Market Perform, 'Pure-Pay'
- B.Riley Resumes QuinStreet, Inc. (QNST) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
